Enzo Biochem testifies Cervical Cancer Biomarker detection test

In order to offer a robust, and economically viable solution for anatomical pathology, Enzo Biochem asserted the authentication of a cervical Cancer biomarker detection test offering a strong and economically- viable solution for anatomical  pathology.

Enzo’s validated p16, a marker used extensively as a key diagnostic and prognostic biomarker of several cancers,  Ki-67, Her2 and p53 are some others to enumerate.

As far as Cancer Diagnostics is concerned, Enzo’s validated p16 offers clear detection of tissue abnormalities including the progression of Cervical Cancer. p16 is used in combination with Enzo’s POLYVIEW detection system’s reduction of false-positives, the economics are substantially enhanced.

Elazar Rabbani, Ph.D., Enzo CEO and Chairman said “By developing our own p16, Ki-67, and p53 tests, among others, and the fact that we have a truly unique integrated capability to develop, evaluate and manufacture these and other diagnostics, we believe we can alleviate pressure on clinical labs by providing low cost, clinically relevant products and services, which is what we are engaged in doing.”